{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:42:27Z","timestamp":1792284147596,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK125760"],"award-info":[{"award-number":["K23DK125760"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"DOI":"10.1007\/s11894-026-01061-2","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:16:36Z","timestamp":1792239396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching from Intravenous to Subcutaneous Infliximab in Children with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-1164","authenticated-orcid":false,"given":"Elizabeth A.","family":"Spencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","volume":"161","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: A user\u2019s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161:47\u201365.","journal-title":"Gastroenterology"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1053\/j.gastro.2024.11.004","volume":"168","author":"MD Kappelman","year":"2025","unstructured":"Kappelman MD, Brensinger C, Parlett LE, Hurtado-Lorenzo A, Lewis JD. Prevalence of pediatric inflammatory bowel disease in the united states: Pooled estimates from three administrative claims data sources. Gastroenterology. 2025;168:980\u2013e22.","journal-title":"Gastroenterology"},{"key":"1061_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe crohn\u2019s disease in children. Gastroenterology. 2007;132:863\u201373. quiz 1165-6.","journal-title":"Gastroenterology"},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","volume":"10","author":"J Hyams","year":"2012","unstructured":"Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391\u2013e91.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MPG.0000000000002141","volume":"68","author":"L de Ridder","year":"2019","unstructured":"de Ridder L, Assa A, Bronsky J, et al. Use of biosimilars in pediatric inflammatory bowel disease: An updated position statement of the pediatric ibd porto group of espghan. J Pediatr Gastroenterol Nutr. 2019;68:144\u201353.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1061_CR6","doi-asserted-by":"crossref","unstructured":"Hughes PM, Pittman N, Benkov K et al. Subcutaneous infliximab in pediatric inflammatory bowel disease: Sustained remission, predictable pharmacokinetics, and real-world us implementation. J Pediatr Gastroenterol Nutr 2026 Oct; 83 (4):703-709.","DOI":"10.1002\/jpn3.70510"},{"key":"1061_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/jpn3.70267","volume":"82","author":"JA Eldredge","year":"2026","unstructured":"Eldredge JA, Kaur R, Chua CW, et al. Subcutaneous infliximab use in children with inflammatory bowel disease in an australian center. J Pediatr Gastroenterol Nutr. 2026;82:439\u201346.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/ibd\/izaf335","volume":"32","author":"EH Boute","year":"2026","unstructured":"Boute EH, Gianolio L, Mahmmod S, et al. Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: A multicenter real-world cohort study. Inflamm Bowel Dis. 2026;32:1086\u201396.","journal-title":"Inflamm Bowel Dis"},{"key":"1061_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S, et al. Subcutaneous infliximab (ct-p13 sc) as maintenance therapy for inflammatory bowel disease: Two randomized phase 3 trials (liberty). Gastroenterology. 2024;167:919\u201333.","journal-title":"Gastroenterology"},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s40261-021-01093-8","volume":"41","author":"M Shirley","year":"2021","unstructured":"Shirley M. Subcutaneous infliximab, ct-p13 sc: A profile of its use in the eu. Clin Drug Investig. 2021;41:1099\u2013107.","journal-title":"Clin Drug Investig"},{"key":"1061_CR11","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/apt.16733","volume":"55","author":"RJ Colman","year":"2022","unstructured":"Colman RJ, Xiong Y, Mizuno T, et al. Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric crohn\u2019s disease. Aliment Pharmacol Ther. 2022;55:593\u2013603.","journal-title":"Aliment Pharmacol Ther"},{"key":"1061_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40262-025-01565-6","volume":"65","author":"Q Zhao","year":"2026","unstructured":"Zhao Q, Jongsma MME, Vuijk SA, et al. Population pharmacokinetics analysis of infliximab in up to 10-year-old patients with paediatric inflammatory bowel disease: Label-recommended dose fails to achieve therapeutic target concentration. Clin Pharmacokinet. 2026;65:81\u201395.","journal-title":"Clin Pharmacokinet"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/jpn3.70158","volume":"81","author":"LM Felipez","year":"2025","unstructured":"Felipez LM, Ali S, de Zoeten EF, et al. North american society for pediatric gastroenterology, hepatology, and nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2025;81:1100\u201317.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: Subcutaneous vs intravenous infliximab ct-p13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160:2340\u201353.","journal-title":"Gastroenterology"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/apt.16770","volume":"55","author":"B Caron","year":"2022","unstructured":"Caron B, Fumery M, Netter P, Peyrin-Biroulet L, Letter. Treatment with subcutaneous ct-p13 in crohn\u2019s disease patients with intravenous infliximab failure. Aliment Pharmacol Ther. 2022;55:508\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1061_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13318-025-00959-y","volume":"50","author":"RA Weersink","year":"2025","unstructured":"Weersink RA, Keizer RJ, Derijks LJJ. Simulated dosing regimens of subcutaneous infliximab in adults and children with inflammatory bowel disease: Exploring switch and initiation strategies. Eur J Drug Metab Pharmacokinet. 2025;50:419\u201330.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1061_CR17","doi-asserted-by":"crossref","unstructured":"Colombel JF, Sandborn WJ, Schreiber S, et al. Subcutaneous infliximab (ct-p13 sc) as maintenance therapy for crohn\u2019s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (liberty). J Crohns Colitis. 2026; 20(70):jjag090.","DOI":"10.1093\/ecco-jcc\/jjag090"},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/apt.70267","volume":"62","author":"JD Chetwood","year":"2025","unstructured":"Chetwood JD, Arzivian A, Tran Y, Paramsothy S, Leong RW. Meta-analysis: Intravenous versus subcutaneous infliximab in inflammatory bowel disease. Aliment Pharmacol Ther. 2025;62:380\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"1061_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000002228","author":"F Cummings","year":"2025","unstructured":"Cummings F, Smith PJ, Fumery M et al (2025) Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: An individual participant data meta-analysis. J Clin Gastroenterol. https:\/\/doi.org\/10.1097\/MCG.0000000000002228","journal-title":"J Clin Gastroenterol"},{"key":"1061_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1007\/s10620-025-08876-5","volume":"70","author":"J Rautakorpi","year":"2025","unstructured":"Rautakorpi J, Kolehmainen S, L\u00f6yttyniemi E, et al. Switching to subcutaneous infliximab maintenance therapy is effective in patients with inflammatory bowel disease. Dig Dis Sci. 2025;70:1457\u201366.","journal-title":"Dig Dis Sci"},{"key":"1061_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","volume":"120","author":"GR Lichtenstein","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, et al. Acg clinical guideline: Management of crohn\u2019s disease in adults. Am J Gastroenterol. 2025;120:1225\u201364.","journal-title":"Am J Gastroenterol"},{"key":"1061_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1053\/j.gastro.2025.09.038","volume":"169","author":"FI Scott","year":"2025","unstructured":"Scott FI, Ananthakrishnan AN, Click B, et al. Aga living clinical practice guideline on the pharmacologic management of moderate-to-severe crohn\u2019s disease. Gastroenterology. 2025;169:1397\u2013448.","journal-title":"Gastroenterology"},{"key":"1061_CR23","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1093\/ibd\/izaf038","volume":"31","author":"S Schreiber","year":"2025","unstructured":"Schreiber S, Colombel JF, Hanauer SB, et al. Comparing outcomes with subcutaneous infliximab (ct-p13 sc) by baseline immunosuppressant use: A post hoc analysis of the liberty-cd and liberty-uc studies. Inflamm Bowel Dis. 2025;31:2714\u201324.","journal-title":"Inflamm Bowel Dis"},{"key":"1061_CR24","doi-asserted-by":"publisher","first-page":"e70205","DOI":"10.1002\/ueg2.70205","volume":"14","author":"JF Colombel","year":"2026","unstructured":"Colombel JF, Danese S, Schreiber S, et al. Impact of immunogenicity on clinical outcomes in patients with moderate-to-severe inflammatory bowel disease receiving subcutaneous infliximab: A post hoc analysis of the liberty trials. United Eur Gastroenterol J. 2026;14:e70205.","journal-title":"United Eur Gastroenterol J"},{"key":"1061_CR25","doi-asserted-by":"crossref","unstructured":"Huguet JM, Mart\u00ed Romero L, Bosc\u00e1-Watts MM, et al. Long-term use of subcutaneous infliximab biosimilar ct-p13 in patients with inflammatory bowel disease in clinical practice. Rev Esp Enferm Dig. 2026.","DOI":"10.17235\/reed.2026.11727\/2025"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1093\/ibd\/izaf172","volume":"31","author":"L Bertani","year":"2025","unstructured":"Bertani L, Ribaldone DG, Bossa F, et al. When to switch to subcutaneous infliximab? The re-watch multicenter study. Inflamm Bowel Dis. 2025;31:3363\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1061_CR27","doi-asserted-by":"publisher","first-page":"i1682","DOI":"10.1093\/ecco-jcc\/jjad212.1060","volume":"18","author":"S Anjie","year":"2024","unstructured":"Anjie S, Jharap B, Jansen JM, et al. P930 rapid symptomatic improvement with subcutaneous infliximab induction treatment for patients with moderate-to-severe crohn\u2019s disease: First results from the direct-cd study. J Crohn\u2019s Colitis. 2024;18:i1682\u20133.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1061_CR28","doi-asserted-by":"publisher","first-page":"otad040","DOI":"10.1093\/crocol\/otad040","volume":"5","author":"K Cerna","year":"2023","unstructured":"Cerna K, Duricova D, Lukas M, et al. Subcutaneous infliximab in refractory crohn\u2019s disease patients: A possible biobetter? Crohns Colitis 360. 2023;5:otad040.","journal-title":"Crohns Colitis 360"},{"key":"1061_CR29","volume-title":"Remicade (infliximab) for injection, for intravenous use [prescribing information]","author":"I Janssen Biotech","year":"2021","unstructured":"Janssen Biotech I. Remicade (infliximab) for injection, for intravenous use [prescribing information]. Horsham, PA: Janssen Biotech, Inc.; 2021."},{"key":"1061_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/03007995.2022.2135836","volume":"39","author":"T Hunter","year":"2023","unstructured":"Hunter T, Komocsar WJ, Colletti RB, et al. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or crohn\u2019s disease. Curr Med Res Opin. 2023;39:63\u20139.","journal-title":"Curr Med Res Opin"},{"key":"1061_CR31","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1016\/S0016-5085(26)03069-6","volume":"170","author":"EA Spencer","year":"2026","unstructured":"Spencer EA, Dervieux T, Chavannes M, Dubinsky MC. Mo1630 weight-dependent variability in infliximab clearance across pediatric and adult ibd: Real world pharmacokinetic insights. Gastroenterology. 2026;170:S\u20131219.","journal-title":"Gastroenterology"},{"key":"1061_CR32","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","volume":"179","author":"MME Jongsma","year":"2020","unstructured":"Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric ibd patients: It is all about the dosing. Eur J Pediatr. 2020;179:1935\u201344.","journal-title":"Eur J Pediatr"},{"key":"1061_CR33","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","volume":"21","author":"A Buisson","year":"2023","unstructured":"Buisson A, Nachury M, Reymond M, et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: The remswitch study. Clin Gastroenterol Hepatol. 2023;21:2338\u2013e463.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1061_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.17822","volume":"59","author":"A Buisson","year":"2024","unstructured":"Buisson A, Nachury M, Bazoge M, et al. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The remswitch-lt study. Aliment Pharmacol Ther. 2024;59:526\u201334.","journal-title":"Aliment Pharmacol Ther"},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.14309\/ajg.0000000000003466","volume":"121","author":"Y Hoffert","year":"2026","unstructured":"Hoffert Y, Wang Z, Fumery M, et al. A risk stratification tool for relapse after intravenous-to-subcutaneous switching of infliximab in patients with inflammatory bowel diseases. Am J Gastroenterol. 2026;121:179\u201386.","journal-title":"Am J Gastroenterol"},{"key":"1061_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MPG.0000000000003838","volume":"77","author":"L Gianolio","year":"2023","unstructured":"Gianolio L, Armstrong K, Swann E, et al. Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy. J Pediatr Gastroenterol Nutr. 2023;77:235\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1061_CR37","first-page":"A57","volume":"17","author":"R Kejariwal","year":"2026","unstructured":"Kejariwal R, Preston C, Barr S, et al. Oc84\u2005substantial cost benefit of switching from intravenous to subcutaneous infliximab in adolescent inflammatory bowel disease. Frontline Gastroenterol. 2026;17:A57.","journal-title":"Frontline Gastroenterol"},{"key":"1061_CR38","doi-asserted-by":"publisher","first-page":"102680","DOI":"10.1016\/j.clinre.2025.102680","volume":"49","author":"AS Duquerois","year":"2025","unstructured":"Duquerois AS, Martinez-Vinson C, Loppinet T, et al. A series of pediatric patients with inflammatory bowel disease switching from intravenous to subcutaneous infliximab maintenance therapy. Clin Res Hepatol Gastroenterol. 2025;49:102680.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1061_CR39","doi-asserted-by":"crossref","unstructured":"Ridder N, Overberg J, Kalveram L et al. Subcutaneous infliximab as a maintenance option in pediatric ibd: a real-world cohort including younger and lower-weight children. Mol Cell Pediatr. 2026;13 (1):38.","DOI":"10.1186\/s40348-026-00251-2"},{"key":"1061_CR40","doi-asserted-by":"crossref","unstructured":"Alberto JR, De La Barreda Heusser L, Marquez Rodriguez JA et al. P0738 real-world experience of switching from intravenous to subcutaneous infliximab in pediatric inflammatory bowel disease patients: a multicenter retrospective cohort from the canary islands, spain. J Crohn\u2019s Colitis. 2026;20 (Supplement_1) ; jjaf231.919.","DOI":"10.1093\/ecco-jcc\/jjaf231.919"},{"key":"1061_CR41","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjac055","volume":"16","author":"MT Dolinger","year":"2022","unstructured":"Dolinger MT, Rolfes P, Spencer E, et al. Outcomes of children with inflammatory bowel disease who develop anti-tumour necrosis factor-induced skin reactions. J Crohns Colitis. 2022;16:1420\u20137.","journal-title":"J Crohns Colitis"},{"key":"1061_CR42","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/jpn3.70275","volume":"82","author":"D Turner","year":"2026","unstructured":"Turner D, Assa A, Malham M, et al. Reshaping study design for faster extrapolation-based drug approval in pediatric inflammatory bowel diseases: An espghan-naspghan position paper. J Pediatr Gastroenterol Nutr. 2026;82:867\u201394.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1061_CR43","doi-asserted-by":"crossref","unstructured":"Ghersin I, Argyriou O, Sahnan K, Warusavitarne J, Hart AL. A pilot study of the effectiveness and safety of subcutaneous infliximab in chronic inflammatory pouch conditions: the st. Mark\u2019s experience. J Clin Med. 2026;15 (5):2053.","DOI":"10.3390\/jcm15052053"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-026-01061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-026-01061-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-026-01061-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:02:48Z","timestamp":1792281768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-026-01061-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1007\/s11894-026-01061-2","relation":{},"ISSN":["1534-312X"],"issn-type":[{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"2 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review synthesizes previously published, de-identified aggregate data and did not require new ethical approval.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.A. Spencer reports research support from the NIH (K23DK125760) and historical service on a single advisory board for Celltrion (relationship now ended).","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A large language model (Claude, Anthropic) was used to assist with table creation as well as for copy-editing.","order":3,"name":"Ethics","label":"Use of Large Language Models","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"34"}}